帕洛诺司琼在晚期肺癌含顺铂方案化疗中预防恶心呕吐效果的临床观察

The clinical observation of palonosetron in preventing nausea and vomiting in advanced lung cancer with cisplatin-based chemotherapy

目的观察帕洛诺司琼在晚期肺癌含顺铂方案化疗中预防恶心呕吐的临床疗效。方法将83例晚期肺癌患者随机分为治疗组和对照组。治疗组42例,化疗期间给予帕洛诺司琼止吐治疗,对照组41例,给予昂丹司琼止吐治疗。观察两组恶心呕吐的控制效果及不良反应。结果治疗组和对照组在急性期的完全缓解率和有效率分别为52.3%vs46.3%和71.4%vs60.9%,两组比较差异均无显著性(P>0.05)。治疗组和对照组在延迟期的完全缓解率和有效率分别为50.0%vs29.4%和76.2%vs51.2%,差异有显著性(P<0.05)。治疗组在急性期和延迟期第一次治疗失败后应用帕洛诺司琼补救治疗的有效率分别为40.0%和60.0%,明显优于昂丹司琼的补救治疗(P<0.05)。两组的不良反应主要为便秘、头痛、口干、皮疹、过敏,两组患者毒副反应的发生率比较差异均无显著性(P>0.05)。结论帕洛诺司琼预防化疗所致的急性恶性呕吐的效果与昂丹司琼相似,但治疗延迟性恶心呕吐及补救治疗的效果明显优于昂丹司琼。

[ Objective ] To observe the clinical effect of palonosetron in preventing nausea and vomiting in ad- vanced lung cancer with cisplatin-based chemotherapy. [ Methods ] A total of 83 cases of advanced lung cancer patients were randomly divided into treatment group and control group. In the treatment group, 42 patients were giv- en antiemetic palonosetron during chemotherapy, in the control group, 41 patients received ondansetron antiemetic therapy. The control rate and adverse were observed. [ Results ] The complete remission rate and effective rates in the acute phase of the treatment group and control group were 52.3% vs 46.3% and 71.4% vs 60.9%, there were no significant statistically difference （P 〉0.05）. The complete remission rate and effective rates in the delayed phase of treatment and control groups were 50.0% vs 29.4% and 76.2% vs 51.2%, there were significant statistically differ- ence（P 〈0.05）.In the treatment group, the effective rates of palonosetron in remedial treatment in the acute phase and delayed phase after failure of first treatment were 40.0% and 60.0%, significantly better than ondansetron for remedi- al treatment （P 〈0.05）. The adverse reactions in two groups were constipation, headache, dry mouth, rash, allergy, there were no significant difference of side effects incidence （P 〉0.05）. [ Conclusion ] Palonosetron was as effective as ondansetron in preventing acute chemotherapy-induced nausea and vomiting, but it is superior to ondansetron inpreventing delayed nausea and vomiting, and remedial treatment.